Mira Pharmaceuticals (MIRA) priced 1.275M shares at $7.00. Kingswood is acting as sole book running manager for the offering. Mira is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new unscheduled synthetic THC analog, MIRA1a, that is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>